Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Teams Up with Chopra Foundation to Foster Psychedelics Therapy Awareness
Dr. Deepak Chopra recently stated that there was an urgent need for more effective treatments in the mental health space, a statement with which Doug Drysdale, CEO of Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), agrees. Drysdale stated that he believed that the largest barrier in the advancement of the flourishing psychedelics industry was the stigmatization and misinformation concerning psychedelic compounds.
He explained that many individuals who weren’t involved in the psychedelics sector knew so little about these compounds and had warped perceptions about what they could do, giving the example of a conversation he had with one scientist who thought that psychedelics were addictive substances that led to suicidal ideation.
Drysdale highlighted that this misinformation shocked him, especially when one considered that this scientist was in a position of influence that enabled them to give advice to regulators.
Cybin is now collaborating with the Chopra Foundation to grow awareness regarding the potential of psychedelic treatments in revolutionizing the treatment of mental health conditions. The psychedelic company will be working with the Chopra Foundation’s Never Alone movement. The foundation, under this initiative, works with other researchers, civic groups and policymakers to advance awareness and education in mental health.
Chopra is a globally renowned pioneer in personal transformation and integrative medicine. This is in addition to being a bestselling author of more than 90 books that explore joyful living, mental wellness, meditation and spirituality. Chopra’s not-for-profit organization is focused on improving the well-being and health of individuals, expanding their consciousness, cultivating spiritual knowledge and promoting world peace around the globe.
Chopra explained that his organization’s movement was focused on joining forces with the best and brightest mental health professionals, policymakers, businesses and others, with the objective of advancing scientific research, building awareness and creating an international community to ensure extensive access to resources on well-being. He added that the number of companies looking into psychedelic-based treatments was increasing and applauded Cybin for growing its leadership position in this burgeoning industry via a scientific approach that delivered the healing properties of various psychedelic substances while diminishing variable side effects that had hindered these compounds from being used as therapies in the past.
Chopra also noted that Cybin’s method was ethical and thoughtful and that it was one of the few companies that could effectively meet the needs of healthcare providers and patients.
Cybin Inc. is a biopharmaceutical company that has built an impressive portfolio made up of psychedelic compounds. It remains committed to ensuring access to resources for mental wellness, especially in underserved communities.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Dr. Deepak Chopra recently stated that there was an urgent need for more effective treatments in the mental health space, a statement with which Doug Drysdale, CEO of Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), agrees. Drysdale stated that he believed that the largest barrier in the advancement of the flourishing psychedelics industry was the stigmatization and misinformation concerning psychedelic compounds.
He explained that many individuals who weren’t involved in the psychedelics sector knew so little about these compounds and had warped perceptions about what they could do, giving the example of a conversation he had with one scientist who thought that psychedelics were addictive substances that led to suicidal ideation.
Drysdale highlighted that this misinformation shocked him, especially when one considered that this scientist was in a position of influence that enabled them to give advice to regulators.
Cybin is now collaborating with the Chopra Foundation to grow awareness regarding the potential of psychedelic treatments in revolutionizing the treatment of mental health conditions. The psychedelic company will be working with the Chopra Foundation’s Never Alone movement. The foundation, under this initiative, works with other researchers, civic groups and policymakers to advance awareness and education in mental health.
Chopra is a globally renowned pioneer in personal transformation and integrative medicine. This is in addition to being a bestselling author of more than 90 books that explore joyful living, mental wellness, meditation and spirituality. Chopra’s not-for-profit organization is focused on improving the well-being and health of individuals, expanding their consciousness, cultivating spiritual knowledge and promoting world peace around the globe.
Chopra explained that his organization’s movement was focused on joining forces with the best and brightest mental health professionals, policymakers, businesses and others, with the objective of advancing scientific research, building awareness and creating an international community to ensure extensive access to resources on well-being. He added that the number of companies looking into psychedelic-based treatments was increasing and applauded Cybin for growing its leadership position in this burgeoning industry via a scientific approach that delivered the healing properties of various psychedelic substances while diminishing variable side effects that had hindered these compounds from being used as therapies in the past.
Chopra also noted that Cybin’s method was ethical and thoughtful and that it was one of the few companies that could effectively meet the needs of healthcare providers and patients.
Cybin Inc. is a biopharmaceutical company that has built an impressive portfolio made up of psychedelic compounds. It remains committed to ensuring access to resources for mental wellness, especially in underserved communities.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
